Skip to main content
SpringerLink
Log in

Apoptosis in health and disease and modulation of apoptosis for therapy: An overview

  • Review Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

Apoptosis a physiological mechanism that eliminates excessive, damaged or unwanted cells, is a highly regulated pathway important for maintaining homeostasis in multicellular organisms. It can be initiated through various signals via the extrinsic pathway which involves death receptors, or via the intrinsic pathway which is initiated by intracellular damage and involves the mitochondria and release of cytochrome c from it to further activate caspases. The Bcl-2 family of proteins is situated upstream to the irreversible damage of cellular constituents and is an important checkpoint in the fate of a cell. The pro-apoptotic members, BH3 only members include BID, BAD and BIM. They directly or indirectly activate multidomain BAX/BAK that constitute the requisite gateway to the intrinsic pathway which operates at the mitochondrial surface and endoplasmic reticulum. In contrast, antiapoptotic members such as Bcl-2, Bcl-XL bind and sequester activation. Downstream of mitochondria, the apoptosome involvement is seen to generate caspase activity. Post mitochondria regulation involves IAPs, and their inhibitors. The pathogenesis of several diseases such as cancer, neurodegenerative disorders, autoimmune disorders, heart disease, infectious diseases including AIDS is closely related to aberrant apoptosis. Consequently interest has emerged in employing various the rapeutic approaches such as gene therapy, antisense therapy, recombinant biologicals, organic and combinatorial chemistry, to specifically target apoptosis signaling pathways such as death receptors FAS/TRAIL, Bcl-2, p53, IAPs, SMAC and caspases, etc. and are now advancing from preclinical to clinical phase.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26:239–57.

    PubMed  CAS  Google Scholar 

  2. Sulston JE, Horvitz HR. Post-embryonic cell lineages of the nematode, Caenorhabditis elegans. Dev Biol 1977; 56:110–56.

    Article  PubMed  CAS  Google Scholar 

  3. Singh N, Anand S. Cell death by apoptosis. Indian J Exp Biol 1994; 32:843–7.

    PubMed  CAS  Google Scholar 

  4. Savill J, Fadock V. Corpse clearance defined the meaning of cell death. Nature 2000; 407:784–88.

    Article  PubMed  CAS  Google Scholar 

  5. Philchenkov AA. Caspases as regulators of apoptosis and other cell functions. Biochemistry (Mosc) 2003; 68:365–76.

    Article  CAS  Google Scholar 

  6. Hengartner MO. The biochemistry of apoptosis. Nature. 2000; 407:770–76.

    Article  PubMed  CAS  Google Scholar 

  7. Wajant H. The Fas signaling pathway: more than a paradigm. Science 2002; 296:1635–36.

    Article  PubMed  CAS  Google Scholar 

  8. Schultz DR, Harrington WJ Jr. Apoptosis: programmed cell death at a molecular level. Semin Arthritis Rheum 2003; 32:345–69.

    Article  PubMed  CAS  Google Scholar 

  9. Rao RV, Ellerby HM, Bredesen DE. Coupling endoplasmic reticulum stress to the cell death program. Cell Death Diff 2004; 11:372–80.

    Article  CAS  Google Scholar 

  10. Singh N. Apoptosis-new concepts in molecular medicine. Ind J Clinical Biochem 1995; 10:54–6.

    Article  Google Scholar 

  11. Singh N, Sun Y, Nakamura K, Smith MR, Colburn NH. C-JUN/AP-1 as possible mediators of tumor necrosis factor-alpha-induced apoptotic response in mouse JB6 tumor cells. Oncology Research 1995; 7:353–62.

    PubMed  CAS  Google Scholar 

  12. Nagata S. Apoptosis by death factor. Cell 1997; 88:355–65.

    Article  PubMed  CAS  Google Scholar 

  13. Reed JC. Bcl-2 family proteins. Oncogene 1998; 17:3225–36.

    Article  PubMed  Google Scholar 

  14. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001; 292:727–30.

    Article  PubMed  CAS  Google Scholar 

  15. Scorrano L, Oakes SA, Opferman JT, Cheng EH, Sorcinelli MD, Pozzan T, et al. BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science 2003; 300:135–9.

    Article  PubMed  CAS  Google Scholar 

  16. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 2001; 8:705–11.

    Article  PubMed  CAS  Google Scholar 

  17. Boatright KM, Renatus M, Scott FL, Sperandio S, Shin H, Pedersen IM, et al. A unified model for apical caspase activation. Mol Cell 2003; 11:529–41.

    Article  PubMed  CAS  Google Scholar 

  18. Philchenkov A. Caspases: potential targets for regulating cell death. J Cell Mol Med 2004; 8:432–44.

    Article  PubMed  CAS  Google Scholar 

  19. Johnson DE. Noncaspase proteases in apoptosis. Leukemia 2000; 14:1695–703.

    Article  PubMed  CAS  Google Scholar 

  20. French LE, Tschopp J. Protein-based therapeutic approaches targeting death receptors. Cell Death Differ 2003; 10:117–23.

    Article  PubMed  CAS  Google Scholar 

  21. Ferri KF, Kroemer G. Organelle-specific initiation of cell death pathways. Nat Cell Biol 2001; 3:E255–63.

    Article  PubMed  CAS  Google Scholar 

  22. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003; 22:8590–607.

    Article  PubMed  CAS  Google Scholar 

  23. Chang DW, Ditsworth D, Liu H, Srinivasula SM, Alnemri ES, Yang X. Oligomerization is a general mechanism for the activation of apoptosis initiator and inflammatory procaspases. J Biol Chem 2003; 278:16466–9.

    Article  PubMed  CAS  Google Scholar 

  24. Guicciardi ME, Leist M, Gores GJ. Lysosomes in cell death. Oncogene 2004; 23:2881–90.

    Article  PubMed  CAS  Google Scholar 

  25. Liston P, Fong WG, Korneluk RG. The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 2003; 22:8568–80.

    Article  PubMed  CAS  Google Scholar 

  26. Vaux DL, Silke J. IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol 2005; 6:287–97.

    Article  PubMed  CAS  Google Scholar 

  27. Cheng EH, Sheiko TV, Fisher JK, Craigen WJ, Korsmeyer SJ. VDAC2 inhibits BAK activation and mitochondrial apoptosis. Science 2003; 301:513–7.

    Article  PubMed  CAS  Google Scholar 

  28. Pinton P, Ferrari D, Rapizzi E, Di Virgilio F, Pozzan T, Rizzuto R. The Ca2+ concentration of the endoplasmic reticulum is a key determinant of ceramide-induced apoptosis: significance for the molecular mechanism of Bcl-2 action. EMBO J 2001; 20:2690–701.

    Article  PubMed  CAS  Google Scholar 

  29. Kagan VE, Gleiss B, Tyurina YY, Tyurin VA, Elenstrom-Magnusson C, Liu SX, et al. A role for oxidative stress in apoptosis: oxidation and externalization of phospatidylserine is required for macrophage clearance of cell under going Fas-mediated apoptosis. J Immunol 2002; 169:487–99.

    PubMed  CAS  Google Scholar 

  30. Lauber K, Blumenthal SG, Waibel M, Wesselborg S. Clearance of apoptotic cells: getting rid of the corpses. Mol Cell 2004; 14:277–87.

    Article  PubMed  CAS  Google Scholar 

  31. Wu Y, Singh S, Georgescu MM, Brige RB. A role for Mer tyrosine kinase in alphavbeta5 integrin-mediated phagocytosis of apoptotic cell. J Cell Sci 2005; 118:539–53.

    Article  PubMed  CAS  Google Scholar 

  32. Fadeel B. Programmed cell clearance. Cell Mol Life 2003; 60:2575–85.

    Article  CAS  Google Scholar 

  33. Huynh ML, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 2002; 109:41–50.

    PubMed  CAS  Google Scholar 

  34. Krammer PH. CD 95's deadly mission in the immune system. Nature 2000; 407:789–95.

    Article  PubMed  CAS  Google Scholar 

  35. Kishimoto H, Sprent J. The thymus and central tolerance. Clin Immunol 2000; 95:S3–7.

    Article  Google Scholar 

  36. Drakesmith H, Chain B, Beverley P. How can dendritic cells cause autoimmune disease? Immunol Today 2000; 21:214–7.

    Article  PubMed  CAS  Google Scholar 

  37. Merry DE, Korsmeyer SJ. Bcl-2 gene family in the nervous system. Annu Rev Neurosci 1997; 20:245–67.

    Article  PubMed  CAS  Google Scholar 

  38. Fadeel B, Orrenius S. Apoptosis: a basic biological phenomenon with wide ranging implication in human disease. J Intern Med 2005; 258:479–517.

    Article  PubMed  CAS  Google Scholar 

  39. Martinon F, Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 2004; 117:561–74.

    Article  PubMed  CAS  Google Scholar 

  40. Ren Y, Tang J, Mok MY, Chan AW, Wu A, Lau CS. Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 2003; 48:2888–97.

    Article  PubMed  Google Scholar 

  41. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002; 2:465–75.

    Article  PubMed  CAS  Google Scholar 

  42. Gregory CD, Devitt A. The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically? Immunology 2004; 113:1–14.

    Article  PubMed  CAS  Google Scholar 

  43. Vandivier RW, Fadok VA, Hoffmann PR, Bratton DL, Penvari C, Brown KK, et al. Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J Clin Invest 2002; 109:661–70.

    PubMed  CAS  Google Scholar 

  44. Henriksen PA, Devitt A, Kotelevtsev Y, Sallenave JM. Gene delivery of the elastase inhibitor elafin protects macrophages from neutrophil elastase-mediated impairment of apoptotic cell recognition. FEBS Lett 2004; 574:80–4.

    Article  PubMed  CAS  Google Scholar 

  45. Orr HT, Zoghbi HY. Reversing neurodegeneration: a promise unfolds. Cell 2000; 101:1–4.

    Article  PubMed  CAS  Google Scholar 

  46. Sanchez I, Xu CJ, Juo P, Kakizaka A, Blenis J, Yuan J. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 1999; 22:623–33.

    Article  PubMed  CAS  Google Scholar 

  47. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003; 34:383–94.

    Article  PubMed  CAS  Google Scholar 

  48. Gill C, Mestril R, Samail A. Losing heart: the role of apoptosis in heart disease—a novel therapeutic target? FASEB J 2002; 16:135–46.

    Article  PubMed  CAS  Google Scholar 

  49. Fulda S, Debatin KM. Targeting apoptosis pathways in cancer therapy. Curr Cancer Drug Target 2004; 4:569–76.

    Article  CAS  Google Scholar 

  50. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Triqiante G, Hsieh JK, Zhong S, et al. ASPP protein specifically stimulates the apoptotic function of p53. Mol Cell 2001; 8:781–94.

    Article  PubMed  CAS  Google Scholar 

  51. Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov 2002; 1:111–21.

    Article  PubMed  CAS  Google Scholar 

  52. Fadeel B. Cell clearance and cancer. In: Sluyser M, ed. Applications of apoptosis to Cancer Treatment. The Netherland: Springer, 2005: 51–84.

    Chapter  Google Scholar 

  53. de la Taille A, Chen MW, Burchardt M, Chopin DK, Buttyan R. Apoptotic conversion: evidence for exchange of genetic information between prostate cancer cells mediated by apoptosis. Cancer Res 1999; 59:5461–3.

    PubMed  Google Scholar 

  54. Fischer U, Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death Differ 2005; 12: Suppl. 1:942–61.

    Article  PubMed  CAS  Google Scholar 

  55. Sandborn WJ, Hanauer S, Loftus EV jr, Tremaine WJ, Kane S, Cohen R, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004; 99:1984–89.

    Article  PubMed  CAS  Google Scholar 

  56. Daniel PT, Wieder T, Sturm I, Schulze-Osthoff K. The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 2001; 15:1022–32.

    Article  PubMed  CAS  Google Scholar 

  57. Nicholson DW. From bench to clinic with apoptosis-based therapeutic agents. Nature 2000; 407:810–16.

    Article  PubMed  CAS  Google Scholar 

  58. Reed JC, Pellecchia M. Apoptosis-based therapies for hematological malignancies. Blood 2005; 106:408–18.

    Article  PubMed  CAS  Google Scholar 

  59. Zangemeister-Wittke U, Leech SH, Olie RA, Simoes-Wust AP, Gautschi, Luedke GH, et al. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 2000; 6:2547–55.

    PubMed  CAS  Google Scholar 

  60. Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 2000; 60:5659–66.

    PubMed  CAS  Google Scholar 

  61. Tamm I, Trepel M, Cardo-Vila M, Sun Y, Welsh K, Cabezas E, et al. Peptides targeting caspase inhibitors. J Biol Chem 2003; 278:14401–5.

    Article  PubMed  CAS  Google Scholar 

  62. Hoglen NC, Chen LS, Fisher CD, Hirakawa BP, Groessi T, Contreras PC. Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a livertargeted caspase inhibitor. J Pharmacol Exp Ther 2004; 309:634–40.

    Article  PubMed  CAS  Google Scholar 

  63. Yang W, Guastella J, Huang JC, Wang Y, Zhang L, Xue D, et al. MX 1013, a dipeptide caspase inhibitor with potent in vivo antiapoptotic activity. Br J Pharmacol 2003; 140:402–12.

    Article  PubMed  CAS  Google Scholar 

  64. Linton SD, Aja T, Allegrini PR, Deckwerth TL, Diaz JL, Hengerer B, et al. Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke. Bioorg Med Chem Lett. 2004; 14:2685–91.

    Article  PubMed  CAS  Google Scholar 

  65. Philchenkov A, Zavelevich M, Kroczak TJ, Los M. Caspases and cancer: mechanisms of inactivation and new treatment modalities. Exp Oncol 2004; 26:82–97.

    PubMed  CAS  Google Scholar 

  66. Xie X, Zhao X, Liu Y, Zhang J, Matusik RJ, Slawin KM, et al. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer. Cancer Res 2001; 61:6795–804.

    PubMed  CAS  Google Scholar 

  67. Komata T, Kondo Y, Kanzawa T, Hirohata S, Koga S, Sumiyoshi H, et al. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res 2001; 61:5796–802.

    PubMed  CAS  Google Scholar 

  68. Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin. Cancer Res. 2003; 9:2826–36.

    PubMed  CAS  Google Scholar 

  69. Stoll R, Renner C, Hansen S, Palme S, Klein C, Belling A, et al. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry. 2001; 40:336–44.

    Article  PubMed  CAS  Google Scholar 

  70. Butz K, Denk C, Ullmann A, Scheffner M, Hoppe-Seyler F. Induction of apoptosis in human papillomavirus positive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci U S A 2000; 97:6693–7.

    Article  PubMed  CAS  Google Scholar 

  71. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004; 305:626–9.

    Article  PubMed  CAS  Google Scholar 

  72. Breckenridge DG, Xue D. Regulation of mitochondrial membrane permeabilization by BCL-2 family proteins and caspases. Curr Opin Cell Biol. 2004; 16:647–52.

    Article  PubMed  CAS  Google Scholar 

  73. Armstrong JS, Jones DP. Glutathione depletion enforces the mitochondrial permeability transition and causes cell death in Bcl-2 overexpressing HL60 cells. FASEB J. 2002; 16:1263–65.

    PubMed  CAS  Google Scholar 

  74. Armstrong JS. Mitochondria: a target for cancer therapy. Br J Pharmacol 2006; 147:239–48.

    Article  PubMed  CAS  Google Scholar 

  75. Marcucci G, Stock W, Dai G, Klisovic RB, Liu S, Klisovic MI, et al. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol 2005; 23:3404–11.

    Article  PubMed  CAS  Google Scholar 

  76. Armstrong JS, Steinauer KK, Hornung B, Irish JM, Lecane P, Birrell GW, et al. Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. Cell Death Diffe. 2002; 9:252–63.

    Article  CAS  Google Scholar 

  77. Costantini P, Jacotot E, Decaudin D, Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 2000; 92:1042–53.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, 110029, New Delhi

    Neeta Singh

Authors
  1. Neeta Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neeta Singh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Singh, N. Apoptosis in health and disease and modulation of apoptosis for therapy: An overview. Indian J Clin Biochem 22, 6–16 (2007). https://doi.org/10.1007/BF02913307

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02913307

Key words

Search

Navigation